Patent SettlementThe settlement agreement with Fresenius provides Exparel exclusivity into 2039, which is viewed as a positive for the stock.
Regulatory ChangeThe NOPAIN reimbursement change, which offers additional reimbursement incentives, is expected to positively impact pricing strategy.
Share RepurchaseA new $300MM share repurchase program has been announced, potentially boosting investor confidence.